Education
About Us
Working with TipRanks
Follow Us
Rory Riggs Insider Profile
11 Followers
Rory Riggs, Director at FibroGen, holds 14.63M shares in Cibus (Ticker: CBUS), holds 0.00 shares in Intra-Cellular Therapies (Ticker: ITCI), holds 420.29K shares in Royalty Pharma (Ticker: RPRX). Most recently, Rory Riggs Bought ― shares of Cibus on Jun 11, 2025 for an estimated value of 500.00.
Profitable Transactions
15 out of 29 Profitable Transactions
Average Return
-2.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Rory Riggs holds in companies
Most Profitable Insider Trade
The most profitable trade made by Rory Riggs
Rory Riggs's Trading History
FibroGen
May 28, 2021
Director
Uninformative Buy
―
$6.90M
Royalty Pharma
Feb 22, 2024
Director
Uninformative Buy
―
$15.60M
Cibus
Jun 11, 2025
Director, Ten Percent Owner
Informative Buy
500.00
$21.80M
Intra-Cellular Therapies
Apr 02, 2025
―
Uninformative Sell
17.36M
$0.00
List of latest transactions for each holding click on a transaction to see Rory Riggs's performance on stock
You May Also Like
Rory Riggs insider profile FAQ
What is the percentage of profitable transactions made by Rory Riggs?
The percentage of profitable transactions made by Rory Riggs is 52%.
What is the average return per transaction made by Rory Riggs?
The average return per transaction made by Rory Riggs is -2.40%.
What stocks does Rory Riggs hold?
Rory Riggs holds: FGEN, RPRX, CBUS, ITCI stocks.
What was Rory Riggs’s latest transaction?
Rory Riggs latest transaction was an Informative Buy of $500.00.
What was Rory Riggs's most profitable transaction?
Rory Riggs’s most profitable transaction was an Informative Sell of RPRX stock on November 21, 2022. The return on the trade was 35.40%.
What is Rory Riggs's role in FibroGen?
Rory Riggs's role in FibroGen is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.